Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.31 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105756 | 0.88 | CENPE (0.60) | CENPEHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL2105793 | 0.88 | CENPE (0.60) | CENPEHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL2104605 | 0.86 | CENPE (0.61) | CENPEHRH3AVPR1BKDM4EALDH1A1 | |
| SCHEMBL2105182 | 0.85 | CENPE (0.61) | CENPEHRH3AVPR1BKDM4EALDH1A1 | |
| SCHEMBL2105606 | 0.84 | CENPE (0.66) | CENPEHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL13637264 | 0.82 | CENPE (0.60) | CENPEHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL2104554 | 0.78 | CENPE (0.62) | CENPEHRH3AVPR1BKDM4EALDH1A1 | |
| SCHEMBL2104181 | 0.77 | CENPE (0.68) | CENPEHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL3226744 | 0.77 | CENPE (0.53) | CENPEHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL2104176 | 0.76 | CENPE (0.80) | CENPEHRH3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 50/4885HRH3 2261/4885AVPR1B 4791/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885HRH3 2581/4885AVPR1B 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.